EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Neurosurgeons’ perspective on surgical treatment of glioblastoma: Practices, beliefs and willingness to randomize in surgical trials

Johnny Duerinck iD, Louise Lescrauwaet, Philipp Karschnia iD, Rebeca Pérez Alfayate, Michael D Jenkinson, Eric Suero Molina, Matthias Simon iD, Jasper Gerritsen, Jorn Van Der Veken iD, Thiebaud Picart, Emilie Le Rhun iD, Giuseppe Minniti und 5 weitere

Neuro-Oncology Advances · 12.01.2026 · 8 (1)

DOI: 10.1093/noajnl/vdag166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 26.06.2026. Verfasst von Johnny Duerinck und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal extent of resection for glioblastoma remains debated, with high-level evidence from randomized controlled trials (RCTs) notably scarce. We aimed to evaluate international surgical practices, perceived quality of evidence, and feasibility of future RCTs through an international survey of neurosurgeons.

Methods

An international survey was distributed via European Organization for Research and Treatment of Cancer (EORTC), European Association of Neurosurgical Societies (EANS), Congress of Neurological Surgeons (CNS), and national societies. We used descriptive statistics to summarize surgical practices and univariate analysis and multivariate regression to identify demographic or institutional factors associated with clinical decision-making.

Results

Responses were received from 328 neurosurgeons across 38 countries. Participation was predominantly from Europe (81.1%), with 12.2% from North America. Most participants (82.9%) practiced in academic centers. While 60.4% identified supramarginal resection (SMR) as the optimal surgical goal, 37.8% aim for complete resection of enhancing tumor (CRET). Overall, 90.2% viewed the evidence for CRET as strong, compared to 63.1% for SMR. Despite these views, 72.6% expressed willingness to randomize patients between CRET and SMR, while 49.4% would be willing to randomize between partial resection and biopsy, if CRET is not feasible. Despite differences in individual practice, willingness to participate in RCTs remained consistent across geographic regions. The incomplete overlap between case-based decisions and general willingness to randomize highlights the importance of case-specific nuances. A paradox was observed where perceived weak evidence correlated with lower willingness to randomize(P < .001).

Conclusion

There is substantial global willingness among neurosurgeons to participate in surgical RCTs for glioblastoma. These findings provide a foundation for designing future international trials to resolve long-standing controversies regarding optimal surgical strategy for glioblastoma.

Schlagwörter

Stichwörter der Autor:innen

clinical equipoiseextent of resection (EOR)glioblastomasupramarginal resectionsurgical randomized controlled trials (RCTs)

Autor:innen und Institutionen

  • Department of Neurosurgery, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Neuroprotection and Neuromodulation (NEUR) Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Neurosurgery, Universitaetsklinikum Erlangen-Nuremberg, Friedrich-Alexander-University Erlangen, Erlangen, Germany.
  • Hospital Clínico San Carlos, Madrid, Spain.
  • University of Liverpool, Liverpool, UK.
  • Department of Neurosurgery, University Hospital Münster, Münster, Germany.

ORCID-Profile: Johnny Duerinck, Philipp Karschnia, Matthias Simon, Jorn Van Der Veken, Emilie Le Rhun, Michael Weller, Alireza Mansouri

Zitieren

APA

Duerinck, J., Lescrauwaet, L., Karschnia, P., Alfayate, R. P., Jenkinson, M. D., Molina, E. S., Simon, M., Gerritsen, J., Van Der Veken, J., Picart, T., Le Rhun, E., Minniti, G., Preusser, M., Weller, M., Wittens, M. M. J., Jakola, A. S., & Mansouri, A. (2026). Neurosurgeons’ perspective on surgical treatment of glioblastoma: Practices, beliefs and willingness to randomize in surgical trials. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag166

Vancouver

Duerinck J, Lescrauwaet L, Karschnia P, Alfayate RP, Jenkinson MD, Molina ES, et al. Neurosurgeons’ perspective on surgical treatment of glioblastoma: Practices, beliefs and willingness to randomize in surgical trials. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag166

BibTeX
@article{Duerinck2026,
  author = {Duerinck, Johnny and Lescrauwaet, Louise and Karschnia, Philipp and Alfayate, Rebeca Pérez and Jenkinson, Michael D and Molina, Eric Suero and Simon, Matthias and Gerritsen, Jasper and Van Der Veken, Jorn and Picart, Thiebaud and Le Rhun, Emilie and Minniti, Giuseppe and Preusser, Matthias and Weller, Michael and Wittens, Mandy Melissa Jane and Jakola, Asgeir S and Mansouri, Alireza},
  title = {Neurosurgeons’ perspective on surgical treatment of glioblastoma: Practices, beliefs and willingness to randomize in surgical trials},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/noajnl/vdag166}
}
Kostenlos starten →